Skip to content

Study · Randomized controlled trial · n = 579 · 2025

7 results

Tirzepatide and health-related quality of life in adults with obesity or overweight: Results from the SURMOUNT-3 phase 3 randomized trial.

Gibble TH, Cao D, Forrester T, Fraseur Brumm J, Chao AM

Diabetes, obesity & metabolism14 May 2025Cited by 17 (Europe PMC)

PMID40365662 (opens in a new tab)PMCIDPMC12232368 (opens in a new tab)DOI10.1111/dom.16463 (opens in a new tab)PepBankPUB-40365662
Read at sourcePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with obesity or overweight after a lifestyle programme, tirzepatide gave significantly larger improvements than placebo in most HRQoL measures over 72 weeks.

    In plain wordsIn adults with obesity or overweight, tirzepatide improved most quality-of-life measures more than placebo over 72 weeks.

    Peptide
    Tirzepatide
    Outcome
    IncreaseHealth-related quality of life improvement versus placebo
    Study

    n = 579

    Comparator
    Placebo
    Outcome group
    Quality of life · Whole body
    Studied dose
    maximum tolerated dose (10 or 15 mg) · injection · 72 weeksAs given in this study (human).

    Source sentences

    Summary
    Tirzepatide was associated with significantly larger improvements than placebo in most HRQoL measures from randomization to 72 weeks.
    1 context sentence
    Summary · context
    The randomized population received placebo (N = 292) or tirzepatide maximum tolerated dose (N = 287) for 72 weeks.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with obesity or overweight who had lost weight with lifestyle intervention, tirzepatide for 72 weeks gave significantly more weight loss than placebo.

    In plain wordsIn adults with obesity or overweight, tirzepatide for 72 weeks led to more weight loss than placebo.

    Peptide
    Tirzepatide
    Outcome
    DecreaseBody weight reduction versus placebo
    Study

    n = 579

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    maximum tolerated dose (10 or 15 mg) · injection · 72 weeksAs given in this study (human).

    Source sentences

    Summary
    Adults with obesity/overweight who had already lost ≥5% weight with a 12-week intensive lifestyle programme who then took tirzepatide for 72 weeks not only had significantly more weight loss compared with those taking placebo
    1 context sentence
    Summary · context
    The randomized population received placebo (N = 292) or tirzepatide maximum tolerated dose (N = 287) for 72 weeks.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with obesity or overweight taking tirzepatide for 72 weeks, quality-of-life improvements were observed in physical function.

    In plain wordsIn adults taking tirzepatide for 72 weeks, quality-of-life scores for physical function improved.

    Peptide
    Tirzepatide
    Outcome
    IncreasePhysical function improvement
    Study

    n = 579

    Outcome group
    Quality of life · Whole body
    Studied dose
    maximum tolerated dose (10 or 15 mg) · injection · 72 weeksAs given in this study (human).

    Source sentences

    Summary
    The improvements in QoL were observed in physical function as well as in general mental health and weight-related psychological and social functions.
    1 context sentence
    Summary · context
    The randomized population received placebo (N = 292) or tirzepatide maximum tolerated dose (N = 287) for 72 weeks.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In adults with obesity or overweight taking tirzepatide for 72 weeks, quality-of-life improvements were observed in general mental health.

    In plain wordsIn adults taking tirzepatide for 72 weeks, general mental health scores improved.

    Peptide
    Tirzepatide
    Outcome
    IncreaseGeneral mental health improvement
    Study

    n = 579

    Outcome group
    Quality of life · Mental health and mood
    Studied dose
    maximum tolerated dose (10 or 15 mg) · injection · 72 weeksAs given in this study (human).

    Source sentences

    Summary
    The improvements in QoL were observed in physical function as well as in general mental health and weight-related psychological and social functions.
    1 context sentence
    Summary · context
    The randomized population received placebo (N = 292) or tirzepatide maximum tolerated dose (N = 287) for 72 weeks.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In adults with obesity or overweight taking tirzepatide for 72 weeks, quality-of-life improvements were observed in weight-related psychological and social functions.

    In plain wordsIn adults taking tirzepatide for 72 weeks, weight-related psychological and social functioning improved.

    Peptide
    Tirzepatide
    Outcome
    IncreaseWeight-related psychological and social functioning improvement
    Study

    n = 579

    Outcome group
    Quality of life · Mental health and mood
    Studied dose
    maximum tolerated dose (10 or 15 mg) · injection · 72 weeksAs given in this study (human).

    Source sentences

    Summary
    The improvements in QoL were observed in physical function as well as in general mental health and weight-related psychological and social functions.
    1 context sentence
    Summary · context
    The randomized population received placebo (N = 292) or tirzepatide maximum tolerated dose (N = 287) for 72 weeks.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In adults with obesity or overweight taking tirzepatide, HRQoL improvements were generally numerically larger in those who met greater weight reduction thresholds.

    In plain wordsIn adults taking tirzepatide, quality-of-life gains were generally larger in people who lost more weight.

    Peptide
    Tirzepatide
    Outcome
    IncreaseHRQoL change by weight reduction threshold
    Study

    n: not reported in source

    Outcome group
    Quality of life · Whole body
    Studied dose
    maximum tolerated dose (10 or 15 mg) · injection · 72 weeksAs given in this study (human).

    Source sentences

    Summary
    Improvements in tirzepatide recipients were generally numerically larger in those who met greater weight reduction thresholds.
    2 context sentences
    Summary · context
    In tirzepatide recipients, changes in HRQoL scores from randomization to week 72 were descriptively summarized by achievement of weight reduction thresholds, and for those with versus without physical function limitations at randomization (identified with PGIS for Physical Activity).
    Summary · context
    The randomized population received placebo (N = 292) or tirzepatide maximum tolerated dose (N = 287) for 72 weeks.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In adults with obesity or overweight taking tirzepatide, HRQoL improved more in those with physical function limitations at randomization than in those without.

    In plain wordsIn adults taking tirzepatide, quality of life improved more in people with physical limitations at the start than in those without.

    Peptide
    Tirzepatide
    Outcome
    IncreaseHRQoL change by baseline physical function limitation
    Study

    n: not reported in source

    Comparator
    Participants without physical function limitations
    Outcome group
    Quality of life · Whole body
    Studied dose
    maximum tolerated dose (10 or 15 mg) · injection · 72 weeksAs given in this study (human).

    Source sentences

    Summary
    HRQoL score changes showed greater improvements for adults with versus without physical function limitations for all measures.
    2 context sentences
    Summary · context
    In tirzepatide recipients, changes in HRQoL scores from randomization to week 72 were descriptively summarized by achievement of weight reduction thresholds, and for those with versus without physical function limitations at randomization (identified with PGIS for Physical Activity).
    Summary · context
    The randomized population received placebo (N = 292) or tirzepatide maximum tolerated dose (N = 287) for 72 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:07 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.